Domperidone Exerts Antitumor Activity in Triple-Negative Breast Cancer Cells by Modulating Reactive Oxygen Species and JAK/STAT3 Signaling

The lack of molecular targets hampers the treatment of triple-negative breast cancer (TNBC). In this study, we determined the cytotoxicity of domperidone, a dopamine D2 receptor (DRD2) antagonist in human TNBC BT-549 and CAL-51 cells. Domperidone inhibited cell growth in a dose- and time-dependent m...

Descripción completa

Detalles Bibliográficos
Autores principales: Shakya, Rajina, Byun, Mi Ran, Joo, Sang Hoon, Chun, Kyung-Soo, Choi, Joon-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Applied Pharmacology 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616512/
https://www.ncbi.nlm.nih.gov/pubmed/37899746
http://dx.doi.org/10.4062/biomolther.2023.173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616512/
https://www.ncbi.nlm.nih.gov/pubmed/37899746
http://dx.doi.org/10.4062/biomolther.2023.173

Ejemplares similares